Review of phase 2/3 trials in polymyalgia rheumatica and giant cell arteritis

EXPERT OPINION ON EMERGING DRUGS · Published 2024-01-02 · DOI 10.1080/14728214.2024.2303093

Authors being retrieved — see the publisher record. https://doi.org/10.1080/14728214.2024.2303093

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year: 2024

Related articles

Integration of Clinical, Cytokine, and Ultrasound Data Using Machine Learning Reveals a Multidimensional Inflammatory Signature in Polymyalgia Rheumatica · Journal of Personalized Medicine · 2026 · Cites or is cited by this article
Emerging drugs in phase II and III clinical development for the treatment of alcohol use disorder · EXPERT OPINION ON EMERGING DRUGS · 2024 · Same journal
Emerging drugs for the treatment of irritability associated with autism spectrum disorder · EXPERT OPINION ON EMERGING DRUGS · 2024 · Same journal
At the forefront of gene-based therapies in Dravet syndrome · EXPERT OPINION ON EMERGING DRUGS · 2026 · Same journal
Emerging treatments for sarcoma: from 2024 onward · EXPERT OPINION ON EMERGING DRUGS · 2025 · Same journal
Emerging biological treatments for asthma · EXPERT OPINION ON EMERGING DRUGS · 2025 · Same journal
Emerging immunotherapeutic strategies for cutaneous lupus erythematosus: an overview of recent phase 2 and 3 clinical trials · EXPERT OPINION ON EMERGING DRUGS · 2023 · Same journal
An update on emerging drugs for the treatment of idiopathic pulmonary fibrosis: a look towards 2023 and beyond · EXPERT OPINION ON EMERGING DRUGS · 2023 · Same journal
Potential use of psilocybin drugs in the treatment of depression · EXPERT OPINION ON EMERGING DRUGS · 2023 · Same journal
How will tovorafenib change our treatment of pediatric low-grade glioma? · EXPERT OPINION ON EMERGING DRUGS · 2024 · Same journal